Floatz logo

Cipaglucosidase Alfa-ATGA

Pompe Disease

Amicus Therapeuticsprotein_peptidePhase 1/2Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Pompe Disease cohort.

Asset / SponsorPhaseRating
Avalglucosidase Alfa
Genzyme, a Sanofi Company
Phase 4A
Alglucosidase Alfa
Erasmus Medical Center
Phase 4A
Avalglucosidase Alfa
Genzyme, a Sanofi Company
Phase 4A
Albuterol
National Taiwan University Hospital
Phase 4BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
University of Florida
Phase 4BB

View all 28 →

Same molecule, other indications

Cipaglucosidase Alfa-ATGA is also rated in:

glycogen storage disease due to acid maltase deficiency, late-onsetDormant
BB
Indicative ·
66 / 100
View asset →
glycogen storage disease due to acid maltase deficiency, infantile onsetDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →